According to Merck's latest financial reports the company has $13.19 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2022-12-31 | $13.19 B | 62.94% |
2021-12-31 | $8.09 B | 0.42% |
2020-12-31 | $8.06 B | -22.85% |
2019-12-31 | $10.45 B | 17.89% |
2018-12-31 | $8.86 B | 4.31% |
2017-12-31 | $8.49 B | -40.74% |
2016-12-31 | $14.34 B | 6.81% |
2015-12-31 | $13.42 B | -14.58% |
2014-12-31 | $15.71 B | -10.11% |
2013-12-31 | $17.48 B | 8.33% |
2012-12-31 | $16.14 B | 7.81% |
2011-12-31 | $14.97 B | 22.71% |
2010-12-31 | $12.20 B | 27.03% |
2009-12-31 | $9.60 B | 75.06% |
2008-12-31 | $5.48 B | -33.34% |
2007-12-31 | $8.23 B | -5.53% |
2006-12-31 | $8.71 B | -44.28% |
2005-12-31 | $15.63 B | 120.56% |
2004-12-31 | $7.08 B | 69.9% |
2003-12-31 | $4.17 B | -16.06% |
2002-12-31 | $4.97 B | 51.26% |
2001-12-31 | $3.28 B |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | $23.51 B | 78.28% | ๐บ๐ธ USA |
![]() Novartis NVS | $12.26 B | -7.06% | ๐จ๐ญ Switzerland |
![]() Pfizer PFE | $22.73 B | 72.32% | ๐บ๐ธ USA |
![]() Abbott Laboratories ABT | $10.17 B | -22.91% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | $3.66 B | -72.19% | ๐บ๐ธ USA |
![]() Amgen AMGN | $31.56 B | 139.24% | ๐บ๐ธ USA |
![]() Sanofi SNY | $14.35 B | 8.79% | ๐ซ๐ท France |
![]() Bristol-Myers Squibb BMY | $8.99 B | -31.81% | ๐บ๐ธ USA |
![]() GlaxoSmithKline GSK | $8.64 B | -34.50% | ๐ฌ๐ง UK |
![]() Teva Pharmaceutical Industries TEVA | $2.80 B | -78.77% | ๐ฎ๐ฑ Israel |